US provides Ebola treatment for outbreak in Congo, bringing trials closer
The U.S. has provided experimental antibody drugs from Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo to combat a widening Ebola outbreak, specifically the Bundibugyo strain. This marks a shift in U.S. policy, making the drug available for compassionate use and trials in the region.
Why it matters
This development is critical for addressing a severe public health crisis in Congo and Uganda, potentially leading to the first approved treatments for the Bundibugyo Ebola strain and informing future global health responses.
Key Points Mapp Biopharmaceutical antibody, Gilead antivirals expected to be among the first tested for Bundibugyo WHO s Tedros said treatment and prevention drug trials due in coming weeks Bundibugyo has no approved vaccines or treatments, unlike Ebola Zaire Vaccines being developed will take longer A doctor wearing personal protective equipment (PPE) stands near an ambulance at the Ebola Virus Disease Treatment Center at the Bunia General Reference Hospital, one month after cases were confirmed in Bunia, eastern Democratic Republic of Congo, June 15, 2026. REUTERS/Gradel Muyisa Mumbere/File Photo June 23 (Reuters) The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials to fight the widening Ebola outbreak in Democratic Republic of Congo, a Health Department spokesperson said, a shift from its position of making the drug available just for Americans.
CNBC Africa reports on factual news, in this case, a public health development, without apparent political or ideological slant.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in